PHASE 2 TRIAL OF AGEN1423, AN ANTI-CD73-TGF beta-TRAP BIFUNCTIONAL ANTIBODY, IN COMBINATION WITH BALSTILIMAB, WITH OR WITHOUT CHEMOTHERAPY IN SUBJECTS WITH ADVANCED PANCREATIC CANCER
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要